Cited by 2,445PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 159 of the 160 references it cites were found in a registry or an index.

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, Jeffrey A.·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

There are ample genetic and laboratory studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells. Inhibitors targeting this pathway are entering the clinic at a rapid pace. In this Review, the therapeutic potential of drugs targeting PI3K-Akt signalling for the treatment of cancer is discussed. I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clinical development.

Integrity signals

Registry

Crossref · 10.1038/nrc2664

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 retracted

RETRACTED: Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
She, Q., Chandarlapaty, S., Ye, Q., Lobo, J. M., Haskell, K., Leander, K. R., Defeo-Jones, D., Huber, H. E., & Rosen, N. X. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 313
Retracted
Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma
Garcia-Pedrero, J. M., García‐Carracedo, D., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S., & González, M. V. (2004) · International Journal of Cancer · doi:10.1002/ijc.20711 · Cited by 235
Retracted
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation

Show all 160 references

Research works printed but not linked: 1

Bi, L., Okabe, I., Bernard, D. J. & Nussbaum, R. L. Early embryonic lethality in mice deficient in the p110b catalytic subunit of PI3-kinase. Mamm. Genome 13, 169–172 (2002).

Sorted by citations

Items 701–800 of 1,005

MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer
Wu, X., Liu, T., Fang, O., Dong, W., Zhang, F., Leach, L. J., Hu, X., & Luo, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.6594 · Cited by 58
Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model
van Ooijen, H., Hornsveld, M., Veen, C. D.-D., Velter, R., Dou, M., Verhaegh, W., Burgering, B. M. T., & van de Stolpe, A. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.05.020 · Cited by 55
Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities
Millis, S. Z., Jardim, D. L. F., Albacker, L. A., Ross, J. S., Miller, V. A., Ali, S. M., & Kurzrock, R. (2018) · Cancer · doi:10.1002/cncr.31921 · Cited by 56
A mechanistic insight into the biological activities of urolithins as gut microbial metabolites of ellagitannins
Hasheminezhad, S. H., Boozari, M., Iranshahi, M., Yazarlu, O., Sahebkar, A., Hasanpour, M., & Iranshahy, M. (2021) · Phytotherapy Research · doi:10.1002/ptr.7290 · Cited by 58
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α
Gritsman, K., Yuzugullu, H., Von, T., Yan, H., Clayton, L. K., Fritsch, C. M., Maira, S.-M., Hollingworth, G. J., Choi, C. H., Khandan, T., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69927 · Cited by 57
Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model
Yin, T., He, S., Shen, G., Ye, T., Guo, F., & Wang, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3967 · Cited by 55
The role of cell signaling in poxvirus tropism: The case of the M-T5 host range protein of myxoma virus
Werden, S. J., & McFadden, G. (2007) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.08.001 · Cited by 57
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms
Pérez‐Lorenzo, R., Gill, K. Z., Shen, C., Zhao, F., Zheng, B., Schulze, H.-J., Silvers, D. N., Brunner, G., & Horst, B. A. J. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.511 · Cited by 55
Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling
Fulda, S. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.04.011 · Cited by 58
Molecular Predictors of Response to Antiangiogenesis Therapies
Gerger, A., LaBonte, M. J., & Lenz, H. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212db3c · Cited by 55
Emerging Therapeutic Biomarkers in Endometrial Cancer
Dong, P., Kaneuchi, M., Konno, Y., Watari, H., Sudo, S., & Sakuragi, N. (2013) · BioMed Research International · doi:10.1155/2013/130362 · Cited by 56
New developments in the treatment of ovarian cancer—future perspectives
Lopez, J. S., Banerjee, S. N., & Kaye, S. B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt475 · Cited by 55
Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status
Buontempo, F., Erşahin, T., Missiroli, S., Şentürk, Ş., Etro, D., Öztürk, M., Capitani, S., Çetin-Atalay, R., & Neri, L. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9486-3 · Cited by 55
Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts
Feng, M.-X., Hong, J.-X., Wang, Q., Fan, Y., Yuan, C., Lei, X., Zhu, M., Qin, A., Chen, H., & Hong, D. (2016) · Scientific Reports · doi:10.1038/srep19074 · Cited by 55
The PEAK1–PPP1R12B axis inhibits tumor growth and metastasis by regulating Grb2/PI3K/Akt signalling in colorectal cancer
Ding, C., Tang, W., Wu, H., Fan, X., Luo, J., Feng, J., Wen, K., & Wu, G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.014 · Cited by 54
Oleic acid induces migration through a FFAR1/4, EGFR and AKT-dependent pathway in breast cancer cells
Marcial-Medina, C., Ordoñez-Moreno, A., González‐Reyes, C., Cortés‐Reynosa, P., & Salazar, E. P. (2019) · Endocrine Connections · doi:10.1530/ec-18-0543 · Cited by 57
Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model
Shi, H., Wu, Y., Wang, Y., Zhou, M., Yan, S., Chen, Z., Gu, D., & Cai, Y. (2015) · Nutrition and Cancer · doi:10.1080/01635581.2015.1037962 · Cited by 54
Morin fosters apoptosis in experimental hepatocellular carcinogenesis model
Venkatabalasubramanian, S., & Devaraj, S. N. (2009) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2009.11.011 · Cited by 54
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
Mortensen, D. S., Fultz, K. E., Xu, S., Xu, W., Packard, G. K., Khambatta, G., Gamez, J. C., Leisten, J. C., Zhao, J., Apuy, J. L., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1052 · Cited by 54
The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
Martelli, A. M., Evangelisti, C., Chiarini, F., Grimaldi, C., & McCubrey, J. A. (2010) · Cancers · doi:10.3390/cancers2031576 · Cited by 57
Molecular signaling cascades involved in nonmelanoma skin carcinogenesis
Feehan, R. P., & Shantz, L. M. (2016) · Biochemical Journal · doi:10.1042/bcj20160471 · Cited by 54
Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
Liu, Y., Wan, W.-Z., Li, Y., Zhou, G.-L., & Liu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.12742 · Cited by 54
Suppression of Fatty Acid and Triglyceride Synthesis by the Flavonoid Orientin through Decrease of C/EBPδ Expression and Inhibition of PI3K/Akt-FOXO1 Signaling in Adipocytes
Nagai, S., Matsumoto, C., Shibano, M., & Fujimori, K. (2018) · Nutrients · doi:10.3390/nu10020130 · Cited by 56
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens
Wu, Y.-Y., Wu, H., Wu, J.-E., Huang, K., Yang, S., Chen, S.-X., Tsao, C.-J., Hsu, K., Chen, Y., & Hong, T.-M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1282-0 · Cited by 59
Protein Kinase CK2 in Cancer Energetics
Silva-Pavez, E., & Tapia, J. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00893 · Cited by 54
Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy
Hu, X., Xia, M., Wang, J., Yu, H., Chai, J., Zhang, Z., Sun, Y., Su, J., & Sun, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110397 · Cited by 55
p38γ Mitogen-Activated Protein Kinase Contributes to Oncogenic Properties Maintenance and Resistance to Poly (ADP-Ribose)-Polymerase-1 Inhibition in Breast Cancer
Meng, F., Zhang, H., Liu, G., Kreike, B., Chen, W., Sethi, S. N., Miller, F. R., & Wu, G. (2011) · Neoplasia · doi:10.1593/neo.101748 · Cited by 53
The role of mitochondria in the oncogenic signal transduction
Frezza, C. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.12.013 · Cited by 53
Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase
Dbouk, H. A., Khalil, B. D., Wu, H., Shymanets, A., Nürnberg, B., & Backer, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063833 · Cited by 53
Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies
Bagrodia, S., Smeal, T., & Abraham, R. T. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12007 · Cited by 56
Current and future directions in mammalian target of rapamycin inhibitors development
Fasolo, A., & Sessa, C. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.541154 · Cited by 57
Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter
Whitehead, M. A., Bombardieri, M., Pitzalis, C., & Vanhaesebroeck, B. (2012) · Biochemical Journal · doi:10.1042/bj20112214 · Cited by 54
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy
Ding, C., Chen, S., Zhang, C., Hu, G., Zhang, W., Li, L., Chen, Y., Tan, C., & Jiang, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.10.006 · Cited by 53
miR-718 represses proinflammatory cytokine production through targeting phosphatase and tensin homolog (PTEN)
Kalantari, P., Harandi, O. F., Agarwal, S., Rus, F., Kurt‐Jones, E. A., Fitzgerald, K. A., Caffrey, D. R., & Golenbock, D. T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.749325 · Cited by 54
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Jiang, W., & Ji, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.006 · Cited by 55
Lipid Transfer Proteins and Membrane Contact Sites in Human Cancer
Peretti, D., Kim, S., Tufi, R., & Lev, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00371 · Cited by 51
Inhibition of the PI3K-AKT-mTOR pathway suppresses the adipocyte-mediated proliferation and migration of breast cancer cells
Park, J.-Y., Kang, S., Ahn, K. S., Um, J., Yang, W. M., Yun, M., & Lee, S. (2020) · Journal of Cancer · doi:10.7150/jca.37975 · Cited by 56
Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
Chen, Y., Huang, L., Dong, Y., Tao, C., Zhang, R., Shao, H., & Shen, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.573599 · Cited by 56
Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation
Tokuyama, M., Lorin, C., Delebecque, F., Jung, H., Raulet, D. H., & Coscoy, L. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002265 · Cited by 51
Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition
Megiorni, F., McDowell, H. P., Camero, S., Mannarino, O., Ceccarelli, S., Paiano, M., Losty, P. D., Pizer, B. L., Shukla, R., Pizzuti, A., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0228-4 · Cited by 52
Endometriosis-associated Ovarian Clear Cell Carcinoma: A Special Entity?
Sun, Y., & Liu, G. (2021) · Journal of Cancer · doi:10.7150/jca.61107 · Cited by 52
Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research
Son, B., Lee, W., Kim, H., Shin, H., & Park, H. H. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07077-8 · Cited by 55
PDK1 controls upstream PI3K expression and PIP3 generation
Dieterle, A. M., Böhler, P., Keppeler, H., Alers, S., Berleth, N., Drießen, S., Hieke, N., Pietkiewicz, S., Löffler, A. S., Peter, C., et al. (2013) · Oncogene · doi:10.1038/onc.2013.266 · Cited by 54
P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation
Li, P., Goto, H., Kasahara, K., Matsuyama, M., Wang, Z., Yatabe, Y., Kiyono, T., & Inagaki, M. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-10-0883 · Cited by 56
Therapeutic Implications of Targeting AKT Signaling in Melanoma
Madhunapantula, S. V., & Robertson, G. P. (2011) · Enzyme Research · doi:10.4061/2011/327923 · Cited by 57
Therapeutic potential of hyaluronan oligosaccharides for bone metastasis of breast cancer
Urakawa, H., Nishida, Y., Knudson, W., Knudson, C. B., Arai, E., Kozawa, E., Futamura, N., Wasa, J., & Ishiguro, N. (2011) · Journal of Orthopaedic Research® · doi:10.1002/jor.21557 · Cited by 52
Suppression of mTOR via Akt-dependent and -independent mechanisms in selenium-treated colon cancer cells: involvement of AMPK 1
Lee, Y.-K., Park, S. Y., Kim, Y.-M., Kim, D. C., Lee, W. S., Surh, Y., & Park, O. J. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq040 · Cited by 51
Integrin-linked kinase mediates force transduction in cardiomyocytes by modulating SERCA2a/PLN function
Traister, A., Li, M., Aafaqi, S., Lu, M., Arab, S., Radisic, M., Gross, G. J., Guido, F., Sherret, J., Verma, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms5533 · Cited by 54
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era
Seow, H. F., Yip, W. K., & Fifis, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95101 · Cited by 54
Osthole shows the potential to overcome P-glycoprotein-mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway
Wang, H., Jia, X.-H., CHEN, J.-R., Wang, J., & Li, Y. (2016) · Oncology Reports · doi:10.3892/or.2016.4730 · Cited by 52
A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer
Wu, G. J., Kim, D., Kim, J. N., Park, S., Maharjan, S., Koh, H., Moon, K., Lee, Y., & Kwon, H. (2017) · Theranostics · doi:10.7150/thno.21278 · Cited by 52
Molecular Mechanisms of Breast Cancer Metastasis and Potential Anti-metastatic Compounds
Tungsukruthai, S., Petpiroon, N., & Pithi Chanvorachote, B. (2018) · Anticancer Research · doi:10.21873/anticanres.12502 · Cited by 52
Sustainability of coral reefs are affected by ecological light pollution in the Gulf of Aqaba/Eilat
Rosenberg, Y., Doniger, T., & Levy, O. (2019) · Communications Biology · doi:10.1038/s42003-019-0548-6 · Cited by 52
Rosemary Extract Inhibits Proliferation, Survival, Akt, and mTOR Signaling in Triple-Negative Breast Cancer Cells
Jaglanian, A., & Tsiani, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030810 · Cited by 53
Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)
Sabbah, D. A., Hajjo, R., Bardaweel, S. K., & Zhong, H. A. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1924150 · Cited by 52
Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents
Dhuguru, J., & Ghoneim, O. (2022) · Molecules · doi:10.3390/molecules27072294 · Cited by 53
Translational genomics of ovarian clear cell carcinoma
Khalique, S., Lord, C. J., Banerjee, S. N., & Natrajan, R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.025 · Cited by 51
A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells
Lee, H., Kim, S. J., Jung, K. H., Son, M. K., YAN, H. H., Hong, S., & Hong, S. (2013) · Oncology Reports · doi:10.3892/or.2013.2499 · Cited by 51
Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC)
Muenyi, C. S., States, V., Masters, J. H., Fan, T. W. ‐., Helm, C. W., & States, J. C. (2011) · Journal of Ovarian Research · doi:10.1186/1757-2215-4-9 · Cited by 51
Cdh1 inhibits WWP2-mediated ubiquitination of PTEN to suppress tumorigenesis in an APC-independent manner
Liu, J., Wan, L., Liu, J., Yuan, Z., Zhang, J., Guo, J., Malumbres, M., Liu, J., Zou, W., & Wei, W. (2016) · Cell Discovery · doi:10.1038/celldisc.2015.44 · Cited by 51
Elimination of SOX2/OCT4-Associated Prostate Cancer Stem Cells Blocks Tumor Development and Enhances Therapeutic Response
Vaddi, P. K., Stamnes, M. A., Cao, H., & Chen, S. (2019) · Cancers · doi:10.3390/cancers11091331 · Cited by 51
Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer
Wang, X., Jiang, W., Du, Y., Dongqi, Z., Zhang, J., Fang, C., Fang, Y., & Chen, Z.-S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100884 · Cited by 53
Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer
Venkannagari, S., Fiskus, W. C., Peth, K., Atadja, P. W., Hidalgo, M. M., Maitra, A., & Bhalla, K. N. (2012) · Oncotarget · doi:10.18632/oncotarget.724 · Cited by 50
Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection
Kwei, K. A., Baker, J. B., & Pelham, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046518 · Cited by 50
Disruption of Prostate Epithelial Differentiation Pathways and Prostate Cancer Development
Frank, S. B., & Miranti, C. K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00273 · Cited by 53
Autophagy restricts proliferation driven by oncogenic phosphatidylinositol 3-kinase in three-dimensional culture
Chen, N., Eritja, N., Lock, R., & Debnath, J. (2013) · Oncogene · doi:10.1038/onc.2012.277 · Cited by 50
Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
Kashiyama, T., Oda, K., Ikeda, Y., Shiose, Y., Hirota, Y., Inaba, K., Makii, C., Kurikawa, R., Miyasaka, A., Koso, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087220 · Cited by 51
Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma
Kudo, M. (2011) · Digestive Diseases · doi:10.1159/000327562 · Cited by 50
DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer
Li, J., Chen, C. Y., Bi, X., Zhou, C., Huang, T., Ni, C., Yang, P., Chen, S., Ye, M., & Duan, S. (2017) · Gene · doi:10.1016/j.gene.2017.07.082 · Cited by 50
Redox regulation of microRNAs in cancer
Lan, J., Huang, Z., Han, J., Shao, J., & Huang, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.010 · Cited by 49
Biological aspects of chondrosarcoma: Leaps and hurdles
Méry, B., Espenel, S., Guy, J., Rancoule, C., Vallard, A., Aloy, M., Rodriguez‐Lafrasse, C., & Magné, N. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.009 · Cited by 50
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment
Lin, S., Wang, C., Ji, M., Wu, D., Lv, Y., Zhang, K., Dong, Y., Jin, J., Chen, J., Zhang, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00416 · Cited by 50
IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
Zorea, J., Prasad, M., Cohen, L., Li, N., Schefzik, R., Ghosh, S., Rotblat, B., Brors, B., & Elkabets, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1025-8 · Cited by 52
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
Tanaka, S., Batchelor, T. T., Iafrate, A. J., Dias-Santagata, D. C., Borger, D. R., Ellisen, L. W., Yang, D. X., Louis, D. N., Cahill, D. P., & Chi, A. S. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0720-8 · Cited by 48
PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt
Uche, U. N., Piccirillo, A., Kataoka, S., Grebinoski, S., D’Cruz, L. M., & Kane, L. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20172018 · Cited by 50
SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait
Wu, S., & Näär, A. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-46594-x · Cited by 51
The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non‐coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles
Sanaei, M., Khorasani, A. B. S., Pourbagheri‐Sigaroodi, A., Shahrokh, S., Zali, M. R., & Bashash, D. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30655 · Cited by 57
Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
Garrett, J. T., Chakrabarty, A., & Arteaga, C. L. (2011) · Oncotarget · doi:10.18632/oncotarget.409 · Cited by 49
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Keam, B., Kim, S., Ahn, Y., Kim, T. M., Lee, S., Kim, D., & Heo, D. S. (2015) · PubMed · Cited by 49
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor
Dort, M. E. V., Galbán, S., Wang, H., Sebolt, J. S., Whitehead, C. E., Hong, H., Rehemtulla, A., & Ross, B. D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.02.053 · Cited by 49
Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma
Kudo, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i42.6005 · Cited by 49
Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma
Liu, W., Gao, M., Tzen, K., Tsai, C., Hsu, F., Cheng, A., & Cheng, J. C. (2014) · Oncotarget · doi:10.18632/oncotarget.1978 · Cited by 50
Role of Phosphatidylinositol 3,4,5-Trisphosphate in Cell Signaling
Riehle, R. D., Cornea, S., & Degterev, A. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-6331-9_7 · Cited by 49
Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide
Jaime‐Ramirez, A. C., Dmitrieva, N., Yoo, J. Y., Banasavadi‐Siddegowda, Y., Zhang, J., Relation, T., Bolyard, C. M., Wojton, J., & Kaur, B. (2017) · The Journal of Gene Medicine · doi:10.1002/jgm.2942 · Cited by 49
Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway
Xu, Z., Hu, J., Cao, H., Pilo, M. G., Cigliano, A., Shao, Z., Xu, M. M., Ribback, S., Dombrowski, F., Calvisi, D. F., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.158 · Cited by 49
Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
Wu, Y., Huang, Y.-F., Chen, C., Huang, C., & Chou, C.-Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00206 · Cited by 49
IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin
Ma, X., & Bai, Y. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1110 · Cited by 50
Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab
Iida, M., Brand, T. M., Campbell, D. A., Starr, M. M., Luthar, N., Traynor, A. M., & Wheeler, D. L. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24342 · Cited by 48
Involvement of the Syk–mTOR pathway in follicular lymphoma cell invasion and angiogenesis
Fruchon, S., Kheirallah, S., Saati, T. A., Ysebaert, L., Laurent, C., Leseux, L., Fournié, J., Laurent, G., & Bezombes, C. (2011) · Leukemia · doi:10.1038/leu.2011.248 · Cited by 47
Effect of diallyl disulfide on insulin-like growth factor signaling molecules involved in cell survival and proliferation of human prostate cancer cells in vitro and in silico approach through docking analysis
Arunkumar, R. S., Sharmila, G., Perumal, E., Kalimuthu, S., Banudevi, S., Gunadharini, D. N., Selvanesan, B. C., Daisy, P., & Arunakaran, J. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.04.009 · Cited by 50
Distinct and specific roles of AKT1 and AKT2 in androgen-sensitive and androgen-independent prostate cancer cells
Cariaga-Martínez, A. E., López‐Ruiz, P., Nombela-Blanco, M. P., Motiño, O., González‐Corpas, A., Rodríguez‐Ubreva, J., Lobo, M. V. T., Cortés, M. A., & Colás, B. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.03.019 · Cited by 48
Combination of aspartic acid and glutamic acid inhibits tumor cell proliferation
Yamaguchi, Y., YAMAMOTO, K., Sato, Y., Inoue, S., Morinaga, T., & Hirano, E. (2016) · Biomedical Research · doi:10.2220/biomedres.37.153 · Cited by 48
Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability
Patel, L., Chandrasekhar, J., Evarts, J., Forseth, K., Haran, A. C., Ip, C., Kashishian, A., Kim, M., Koditek, D., Koppenol, S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01169 · Cited by 48
PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration
King, H. A., Thillai, K., Whale, A. D., Arumugam, P., Eldaly, H., Kocher, H. M., & Wells, C. M. (2017) · Scientific Reports · doi:10.1038/srep42575 · Cited by 49
Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma
Makinoshima, H., Umemura, S., Suzuki, A., Nakanishi, H., Maruyama, A., Udagawa, H., Mimaki, S., Matsumoto, S., Niho, S., Ishii, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2109 · Cited by 47
Gigantol inhibits proliferation and enhances DDP-induced apoptosis in breast-cancer cells by downregulating the PI3K/Akt/mTOR signaling pathway
Huang, J., Liu, C., Duan, S., Lin, J., Luo, Y., Tao, S., Xing, S., Zhang, X., Du, H., Wang, H., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119354 · Cited by 47
AKT and the Hallmarks of Cancer
Sementino, E., Hassan, D., Bellacosa, A., & Testa, J. R. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1846 · Cited by 54
Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer.
Azodi, M. Z., Rezaei–Tavirani, M., Rahmati-Rad, S., Hasanzadeh, H., Tavirani, M. R., & Seyyedi, S. S. (2015) · Gastroenterology and hepatology from bed to bench. · Cited by 47
Dehydrocostuslactone Suppresses Angiogenesis In Vitro and In Vivo through Inhibition of Akt/GSK-3β and mTOR Signaling Pathways
Wang, C.-Y., Tsai, A.-C., Peng, C.-Y., Chang, Y.-L., Lee, K., Teng, C., & Pan, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031195 · Cited by 47
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer
Vu, T., Sliwkowski, M. X., & Claret, F. X. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.007 · Cited by 47

Authors: Engelman, J. A.
Affiliations: Massachusetts General Hospital (US)
Corresponding author: Engelman, Jeffrey A.
ORCID: Engelman, Jeffrey A.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-08
Volume: 9
Issue: 8
Pages: 550-562
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2664
OpenAlex: W1977267072
Cited by: 2,445
References: 160
Citations by year: 2026: 60 · 2025: 71 · 2024: 75 · 2023: 102 · 2022: 90 · 2021: 125 · 2020: 146 · 2019: 127 · 2018: 163 · 2017: 172 · 2016: 159 · 2015: 210 · 2014: 211 · 2013: 221 · 2012: 184
FWCI: 13.17
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: PI3K/Akt signaling, PI3K inhibitors, AKT inhibitors, cancer therapy, targeted therapy, drug development, tumor cell survival, treatment resistance
MeSH terms: Antineoplastic Agents, Humans, Neoplasms, Protein Kinases, Signal Transduction, Phosphatidylinositol 3-Kinases, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks